1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

ViaLase Receives CE Mark for Its Vialase Laser, a Femtosecond Laser for Glaucoma Treatment

02 Aug 2024
Admin
News Article

ViaLase Receives CE Mark for Its Vialase Laser, a Femtosecond Laser for Glaucoma Treatment

Overview

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, announced that it has received CE (Conformité Européenne) Mark approval in the European Union (EU) for its ViaLase Laser for the treatment of adult patients with primary open-angle glaucoma (POAG).

About ViaLase Laser

The ViaLase Laser combines the precision of a femtosecond laser and the accuracy of micron-level image guidance to deliver a noninvasive glaucoma treatment called femtosecond laser, image-guided, high-precision trabeculotomy, or FLigHT.
This technology addresses a major unmet need for patients who may benefit from a non-pharmacologic, incision-free procedure without compromising their therapeutic goals.

Words from CEO: ViaLase

“The ViaLase Laser represents a monumental transformation in interventional glaucoma care in its potential to deliver surgery-like results without the need for opening the eye and thus, reducing complications associated with more invasive, surgical procedures,” said Tibor Juhasz, PhD, founder and chief executive officer, ViaLase, Inc.
“Early clinical data indicate that FLigHT is safe and effective at lowering intraocular pressure (IOP). We look forward to working with our distribution partners to bring this groundbreaking technology to physicians and patients in Europe.”

Words from CMO: ViaLase

“We have good evidence that early, non-medical intervention offers better long-term disease control and preservation of vision – which is what matters most to patients. I’m delighted that physicians and patients can soon benefit from the ViaLase Laser, which brings a new level of imaging and precision to glaucoma care. Furthermore, the patient’s lens status has no bearing on their ability to undergo FLigHT, expanding access to patients who previously had limited treatment options,” said Richard Lewis, MD, chief medical officer, ViaLase, Inc.

ViaLase Laser: Commercial Rollout

ViaLase anticipates a selective commercial rollout of the ViaLase Laser in key markets later this year.
The company has established formal distributor partnerships with Global Surgical Service (Spain and Portugal) and Teleon Surgical (Germany and Austria).
Each organization has deep ophthalmology experience and an established commercial presence in their markets.
These strategic partnerships will allow for a timely and efficient rollout of the ViaLase Laser to physicians and patients.

Glaucoma Today

Glaucoma affects 76 million people worldwide, a number that is expected to increase to 112 million by 2040, and is the second leading cause of irreversible blindness in the world.
Most forms of glaucoma are chronic and, when left undetected or untreated, lead to irreversible vision loss.
Early detection and treatment are essential to protecting against vision loss, which results when the optic nerve deteriorates, leading to progressive loss of the field of vision.
Lowering IOP and thus reducing visual field progression is the only proven glaucoma treatment today.
The current treatment paradigm typically begins with topical eye drops, then may advance to laser therapy or minimally invasive glaucoma surgery (MIGS), before resorting to invasive, traditional filtration surgery.

About ViaLase, Inc.

ViaLase, Inc. is a globally-minded, venture capital-backed, clinical stage medical technology company located in Aliso Viejo, California.
ViaLase is focused on disrupting the conventional glaucoma treatment paradigm with the introduction of a truly noninvasive, image-guided, femtosecond laser treatment that enhances glaucoma patient care.